

Instruments, Malvern, UK). To determine the particle size, a dilute suspension of nanoparticles (100 µg/ml) was prepared in Milli-Q water, sonicated on an ice-bath for 30 seconds and subjected to particle size measurement.

2.4 SEM Studies

The surface morphology of nanoparticles was characterized by SEM (Zeiss EVO 18 Special Edition, Germany). The nanoparticles were sputtered (Quorum Technologies, Q150T ES) with gold to make them conductive.

2.5 FT-IR Spectral Studies

The chemical integrity of the drug and the polymer matrix was investigated using FT-IR spectra (Perkin-Elmer, California, USA).

2.6 In vitro Release Kinetics Study

In vitro release of EGCG was carried out by dissolving nanoparticles in PBS (pH 7.4) at 37°C [7].

2.7 Cytotoxicity Study

The cytotoxicity studies on K562 cells were performed with different concentrations of free drug and nanoparticles formulations containing different ranges of concentrations of drug by MTT based colorimetric assay [8].

3. Results and Discussion

EGCG may be responsible for most of the anticancer activity of tea [9]. Its anticancer properties can be enhanced by successful nanoformulations and efficient drug delivery mechanisms [10]. EGCG loaded PLGA polymer nanoparticles were prepared and DLS analysis revealed that the formulated nanoparticles had an average diameter of 300.8 ± 2.6 nm (Figure 2).




Figure 2: Hydrodynamic size measurement by dynamic light scattering

SEM image identified the surface morphology of drug-loaded nanoparticles to be spherical with smooth exterior (Figure 3).




Figure 3: Scanning electron micrograph of EGCG loaded PLGA nanoparticles.

Information on the nature of the molecular interaction within the solid matrix of the nanoparticles was obtained using FT-IR. The spectra for free PLGA nanoparticles showed the characteristic bands of the polymer, $-\text{CH}$, $-\text{CH}_2$, $-\text{CH}_3$ stretching ($2850\text{--}3000\text{ cm}^{-1}$), carbonyl $-\text{C}=\text{O}$ stretching ($1700\text{--}1800\text{ cm}^{-1}$), $\text{C}-\text{O}$ stretching ($1050\text{--}1250\text{ cm}^{-1}$) [11], [12]. FT-IR spectra for EGCG exhibited the characteristic bands corresponding to $-\text{OH}$ stretching ($3600\text{--}3200\text{ cm}^{-1}$), $\text{C}=\text{C}$ stretching ($1600\text{--}1400\text{ cm}^{-1}$), $\text{C}-\text{O}$ stretching of the oxygen in the ring (1272 cm^{-1}). These findings are in agreement with previous studies [13], [14]. In spectra of EGCG loaded nanoparticles, the intensity of $-\text{CH}$, $-\text{CH}_2$, $-\text{CH}_3$ stretching, and $\text{C}=\text{O}$ stretching decreased compared to void PLGA.




Figure 4: FT-IR spectra of EGCG, void PLGA nanoparticles, and EGCG loaded PLGA nanoparticles. (from top to bottom)

There is also a shift in $\text{C}=\text{O}$ stretching peak position from 1802 cm^{-1} in void PLGA to 1794 cm^{-1} in loaded PLGA suggesting active participation of carbonyl group in the interaction. FT-IR measurement evidenced the encapsulation of EGCG within the polymer nanoparticles (Figure 4).




Figure 5: *In vitro* release of EGCG from nanoparticles.

The *in vitro* release of EGCG from PLGA nanoparticles is shown in Figure 5. Around 80% of EGCG is released in first three days, followed by very slow release upto five days and maximum of 90%. Gradual release of drug for longer periods time was achieved by this encapsulation and attempts to increase release time is under process. However, initial burst release was followed by a slower sustained release of EGCG present inside the core of nanoparticles [7], [15].




Figure 6: Dose dependent cytotoxicity of different concentration of void PLGA nanoparticles, EGCG, and EGCG loaded PLGA nanoparticles (from top to bottom)

To investigate the therapeutic efficiency of these formulations, K562 cells were treated with different concentrations of nanoparticles for 24 hours, and cell proliferation was measured by MTT assay. It can be seen from Figure 6 that nanoparticles exhibited significantly higher cytotoxicity compared to EGCG in solution. This observation indicates that EGCG loaded nanoparticles enhances the *in vitro* cancer cell death.

4. Conclusion

A novel biodegradable nanoparticle system has been developed for controlled delivery of EGCG, which is more effective in successful killing of cancer cells than EGCG alone. However, more work in this direction is required to promote this formulation as cancer therapeutic nanomedicine. In general, our results have important implications for the design and fabrication of polymeric nanoparticle delivery systems for bioactive compounds with beneficial effects on human health.

Acknowledgments

Senior research fellow Mr. Sandip Pal is financially supported by Indian Council of Medical Research (ICMR) and is thankful to the same. Dr. Chabita Saha is thankful to Department of Science and Technology (DST), Govt. of India for the financial support. The authors wish to express their gratitude to Dr. Abhijit Saha of University Grant Commission-Department of Atomic Energy (UGC-DAE) Consortium for Scientific Research, Kolkata, for providing the DLS and FT-IR facility and his whole hearted co-operation throughout the work.

References

- [1] G. Y. Yang, J. Liao, K. Kim, E. J. Yurkow, C. S. Yang, "Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols," *Carcinogenesis*, 19, pp. 611-616, 1998.
- [2] Y. H. Cao, R. H. Cao, "Angiogenesis inhibited by drinking tea," *Nature*, 398, pp. 381, 1999.
- [3] N. Ahmad, D. K. Feyes, A. L. Nieminen, R. Agarwal, H. Mukhtar, "Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells," *Journal of National Cancer Institute*, 89, pp. 181-1886, 1997.
- [4] K. Cho, X. Wang, S. Nie, Z. G. Chen, D. M. Shin, "Therapeutic nanoparticles for drug delivery in cancer," *Clinical Cancer Research*, 14, pp. 1310-1316, 2008.
- [5] C. Gomez-Gaete, "Encapsulation of dexamethasone into biodegradable polymeric nanoparticles," *International Journal of Pharmacology*, 331, pp. 153-159, 2007.
- [6] P. Ader, A. Wessmann, S. Wolfram, "Bioavailability and metabolism of the flavonol quercetin in the pig," *Free Radical Biology and Medicine*, 28, pp. 1056-1067, 2000.
- [7] R. Mishra, S. K. Sahoo, "Coformulation of doxorubicin and curcumin in poly-(d,l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells," *Molecular Pharmaceutics*, 8, pp. 852-866, 2011.
- [8] S. Pal, S. K. Dey, C. Saha, "Inhibition of catalase by tea catechins in free and cellular state: a biophysical approach," *Plos One*, 9(7), e102460, 2014.
- [9] J. Jankun, S. H. Selman, R. Swiercz, "Why drinking green tea cloud prevent cancer," *Nature*, 387, pp. 561, 1997.
- [10] C. C. Chen, D. S. Hsieh, K. J. Huang, Y. L. Chan, P. D. Hong, M. K. Yeh, C. J. Wu, "Improving anticancer

efficacy of (-)-epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells,” *Drug Design, Development and Therapy*, 8, pp. 459-474, 2014.

- [11] R. M. Mainardes, R. C. Evangelista, “PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution,” *International Journal of Pharmaceutics*, 290, pp. 137-144, 2005.
- [12] R. M. Mainardes, M. P. D. Gremiao, R. C. Evangelista, “Thermoanalytical study of praziquantel-loaded PLGA nanoparticles,” *Brazilian Journal of Pharmaceutical Sciences*, 42, pp. 523-530, 2006.
- [13] K. Dias, S. Nikolaou, W. F. De Giovanni, “Synthesis and spectral investigation of Al(III) catechin/ β -cyclodextrin and Al(III) quercetin/ β -cyclodextrin inclusion compounds,” *Spectrochimica Acta A*, 70, pp. 154-161, 2008.
- [14] M. M. Ramos-Tejada, J. D. G. Duran, A. Ontiveros-Ortega, M. Espinosa-Jimenez, R. Perea-Carpio, E. Chibowski, “Investigation of alumina/(+)-catechin system properties. Part I: a study of the system by FTIR-UV-Vis spectroscopy,” *Colloids and Surfaces B*, 24, pp. 297-308, 2002.
- [15] S. Acharya, F. Dilnawaz, S. K. Sahoo, “Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy,” *Biomaterials*, 30, pp. 5737-5750, 2009

Author Profile



Sandip Pal received the B.Sc. and M.Sc. degrees in Zoology from University of Calcutta in 2006 and 2008, respectively. During 2010-2015, he pursued his Doctoral Studies from Department of Biotechnology, West Bengal University of Technology. He is currently appointed as Assistant Professor in Post-Graduate Department of Zoology, Asutosh College, Kolkata.



Chabita Saha received the B.Sc. and M.Sc. degrees in Chemistry from University of Burdwan in 1986 and 1988, respectively. She received PhD degree from University of Calcutta in 1996. She is currently working as Scientist in Department of Biotechnology, West Bengal University of Technology.